PMID- 24972718
OWN - NLM
STAT- MEDLINE
DCOM- 20150302
LR  - 20140718
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 13
IP  - 8
DP  - 2014 Aug
TI  - Folate supplementation reduces the side effects of methotrexate therapy for 
      psoriasis.
PG  - 1015-21
LID - 10.1517/14740338.2014.933805 [doi]
AB  - INTRODUCTION: Methotrexate (MTX) is an effective treatment option for patients 
      with moderate-to-severe psoriasis. As psoriasis is an incurable disease, the goal 
      of the MTX treatment is to suppress psoriasis, achieving long-term remissions 
      with minimal treatment-related adverse events (AEs). AREAS COVERED: 
      Supplementation with folate - either folic acid (FA) or folinic acid - may reduce 
      the side effects of MTX therapy. There are no consistent, evidence-based 
      guidelines for folate supplementation in this clinical setting. We present data 
      concerning the impact of folic supplementation on the safety and efficacy of MTX 
      therapy for psoriasis. An extensive search (1960 - March 2014) identified few 
      studies addressing with just one randomized controlled trial (RCT) and some case 
      series. This meager yield underlines the need for further studies, especially 
      RCTs, in this group of patients. EXPERT OPINION: FA may be effective in 
      diminishing the severity of AEs in patients with psoriasis treated with MTX and 
      should be recommended. Supplementation with too high doses of FA may influence 
      the efficacy of treatment.
FAU - Baran, Wojciech
AU  - Baran W
AD  - Wroclaw Medical University, Department of Dermatology, Venereology and 
      Allergology , Chalubinskiego 1, 50-368 Wroclaw , Poland.
FAU - Batycka-Baran, Aleksandra
AU  - Batycka-Baran A
FAU - Zychowska, Magdalena
AU  - Zychowska M
FAU - Bieniek, Andrzej
AU  - Bieniek A
FAU - Szepietowski, Jacek C
AU  - Szepietowski JC
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140627
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Antirheumatic Agents)
RN  - 12001-76-2 (Vitamin B Complex)
RN  - 935E97BOY8 (Folic Acid)
RN  - Q573I9DVLP (Leucovorin)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Antirheumatic Agents/adverse effects/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Folic Acid/administration & dosage/*therapeutic use
MH  - Humans
MH  - Leucovorin/administration & dosage/*therapeutic use
MH  - Methotrexate/*adverse effects/therapeutic use
MH  - Psoriasis/drug therapy/pathology
MH  - Severity of Illness Index
MH  - Vitamin B Complex/administration & dosage/therapeutic use
OTO - NOTNLM
OT  - folic acid supplementation
OT  - methotrexate
OT  - psoriasis
EDAT- 2014/06/29 06:00
MHDA- 2015/03/03 06:00
CRDT- 2014/06/29 06:00
PHST- 2014/06/29 06:00 [entrez]
PHST- 2014/06/29 06:00 [pubmed]
PHST- 2015/03/03 06:00 [medline]
AID - 10.1517/14740338.2014.933805 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2014 Aug;13(8):1015-21. doi: 10.1517/14740338.2014.933805. 
      Epub 2014 Jun 27.